Skip to content

Perceptive Advisors portfolio · Q1 2026

Perceptive Advisors LLC · CIK 0001224962 ·13F filings on SEC EDGAR

In Q1 2026, Perceptive Advisors LLC reported 94 positions worth $5.1B. Its largest holding was PRAX at 12.8% of the portfolio, and the top 10 made up 51%. Its largest new position was MRNA ($50.8M), and it sold out of XBI.

Portfolio value
$5.1B
Positions
94
Top 10 share
51.4%
Changes vs Dec 31, 2025
  • NEW 20
  • ADD 23
  • REDUCE 33
  • EXIT 42

Portfolio map

NEWADDHOLDREDUCE

Each box is a position sized by its value. Color shows the change in shares from the previous quarter. The smallest 54 positions are grouped as one box.

Portfolio history

Q4 2025 to Q1 2026, 2 quarters

Weight of the largest holdings

The 7 holdings with the highest weight in any quarter shown, stacked with all others to 100%.

PRAXCELCASCENDIS PHARMA A/SRYTMROIVCNTASYREOther

Holding timeline

Shade shows the weight in each quarter. A blank cell means the holding was not reported that quarter.

< 1%1–3%3–6%6–10%10–20%20–35%≥ 35%

Holdings

Click a holding to see its price chart with the quarters the investor bought or sold.

NameWeightAvg. cost (est.)Latest priceGain/lossValue
MRNAPut
MODERNA INC
0.99%———$50.8M
15102KAA8
Celcuity Inc.
PRN
0.31%———$15.9M
OCULCall
OCULAR THERAPEUTIX INC
0.08%———$4.2M

Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Mar 31, 2016, when our collected history starts, so the average starts from that quarter's price.

Changes in shares

Change in shares held vs Dec 31, 2025, for the 20 largest positions that changed. Bars are capped at ±100%; the label shows the actual change.

NEWADDREDUCEEXIT

Sold out this quarter

Held on Dec 31, 2025 and not reported for Q1 2026.

StockPrior weightPrior sharesPrior valueChange
XBIPut
SS SPDR S&P BIOTECH ETF
2.39%1,100,000$134.1MEXIT
EXAS
EXACT SCIENCES CORP
2.17%1,200,487$121.9MEXIT
ACLX
ARCELLX INC
1.70%1,466,071$95.6MEXIT
BSX
BOSTON SCIENTIFIC CORP
1.66%979,000$93.3MEXIT
FOLD
AMICUS THERAPEUTICS INC
1.62%6,370,851$90.7MEXIT
ATXS
ASTRIA THERAPEUTICS INC
1.51%6,485,420$84.9MEXIT
DHR
DANAHER CORP
0.82%200,000$45.8MEXIT
CDTX
CIDARA THERAPEUTICS INC
0.65%165,131$36.5MEXIT
IRON
DISC MEDICINE INC
0.64%450,743$35.8MEXIT
PEN
PENUMBRA INC
0.61%110,529$34.4MEXIT
CAI
CARIS LIFE SCIENCES INC
0.55%1,136,206$30.7MEXIT
RAPT
RAPT THERAPEUTICS INC
0.50%825,890$28MEXIT
PVLA
PALVELLA THERAPEUTICS INC
0.50%266,287$27.9MEXIT
KOD
KODIAK SCIENCES INC
0.42%848,900$23.7MEXIT
BIIB
BIOGEN INC
0.39%124,000$21.8MEXIT
ALDX
ALDEYRA THERAPEUTICS INC
0.39%4,185,632$21.7MEXIT
MIRM
MIRUM PHARMACEUTICALS INC
0.37%259,545$20.5MEXIT
GRAL
GRAIL INC
0.36%237,342$20.3MEXIT
CVS
CVS HEALTH CORP
0.31%220,000$17.5MEXIT
GKOS
GLAUKOS CORP
0.28%140,000$15.8MEXIT
DXCM
DEXCOM INC
0.27%225,758$15MEXIT
SVRA
SAVARA INC
0.26%2,400,000$14.5MEXIT
SEPN
SEPTERNA INC
0.22%433,160$12.1MEXIT
38341P102
GOSSAMER BIO INC
0.17%3,139,669$9.7MEXIT
MPLT
MAPLIGHT THERAPEUTICS INC
0.17%550,000$9.7MEXIT
XENE
XENON PHARMACEUTICALS INC
0.16%200,791$9MEXIT
KMTS
KESTRA MEDICAL TECHNOLOGIES
0.13%285,000$7.6MEXIT
CAPRCall
CAPRICOR THERAPEUTICS INC
0.12%242,100$7MEXIT
BHVNCall
BIOHAVEN LTD
0.10%500,000$5.6MEXIT
KYMR
KYMERA THERAPEUTICS INC
0.10%69,935$5.4MEXIT
PEPG
PEPGEN INC
0.10%829,870$5.4MEXIT
TECXCall
TECTONIC THERAPEUTIC INC
0.09%250,000$5.2MEXIT
AQST
AQUESTIVE THERAPEUTICS INC
0.09%747,193$4.8MEXIT
KRYS
KRYSTAL BIOTECH INC
0.08%17,500$4.3MEXIT
OLMA
OLEMA PHARMACEUTICALS INC
0.07%165,713$4.1MEXIT
SDGR
SCHRODINGER INC
0.06%202,400$3.6MEXIT
IMMX
IMMIX BIOPHARMA INC
0.03%338,941$1.8MEXIT
LXEO
LEXEO THERAPEUTICS INC
0.02%139,835$1.4MEXIT
LENZ
LENZ THERAPEUTICS INC
0.01%50,000$800KEXIT
BDSX
BIODESIX INC
0.01%108,694$739.1KEXIT
29415J106
ENVVENO MEDICAL CORPORATION
0.01%1,759,035$564.3KEXIT
IOVA
IOVANCE BIOTHERAPEUTICS INC
0.01%152,714$416.9KEXIT

SEC filings for Q1 2026